Case ReportInternational Journal of Community Medicine and Public Health

Publication:
Development of autoimmune pemphigus vulgaris following Chadox1 nCov-19 coronavirus vaccine (recombinant)

Int J Community Med Public Health. 2023;10(7):2591-2593.DOI10.18203/2394-6040.ijcmph20232059

Thumbnail Image
View on the journal's website(opens in a new tab)

Abstract

Pemphigus vulgaris is a rare IgG-mediated autoimmune disease that affects the skin and mucous membranes, causing painful blistering. Pemphigus vulgaris has been reported to be triggered or exacerbated by various factors, including genetic vulnerability, certain drugs, and malignant diseases. We present a case of a patient who was admitted to the dermatology ward with complaints of multiple fluid-filled lesions, initially over the chest, containing clear fluid-filled, ruptured within 1 to 2 hours to leave behind painful raw areas, predominantly over the trunk, scalp, face, upper limbs in the past 2 weeks, and single raw erosions inside the oral cavity after receiving the second dose of Chadox1 nCov-19 coronavirus vaccine (Covishield™), and also mentioned he had developed similar symptoms after the 1st dose of COVID vaccine. We chose to report this case because of the unusual presentation of a rare COVID vaccine adverse drug reaction seen in India.

Keywords

Affiliations

  1. Doctor of Pharmacy, CMR College of Pharmacy, Kandlakoya, Medchal, Hyderabad, India

Full item record